By SPC News Staff
The FDA granted approval to atezolizumab injection (Tecentriq, Genentech) to treat patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 